

Oligomenorrhea

[View the current Oligomenorrhea InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Oligomenorrhea.html)

(<http://www.bioportfolio.com/indepth/Oligomenorrhea.html>)

Oligomenorrhea is the medical term for infrequent or light menstrual periods in women of child-bearing age. Oligomenorrhea can also be a result of prolactinomas. May also be caused by thyrotoxicosis and Graves disease.



Recent Publications on Oligomenorrhea:

- [Menstrual cycle and its disorders in women with congenital heart disease.](#)
OBJECTIVES: To investigate the age at menarche, the prevalence of... 22nd August, 2008
Department of Cardiology, University Medical Center Groningen, Groningen,- *Congenit Heart Dis.* 2008 Jul;3(4):277-83. ([DOI Direct Link](#))
- [A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka.](#)
In most of South Asia, prevalences and phenotypes of polycystic ovary... 22nd August, 2008
Public Health Complex, Ministry of Health, Colombo, Sri Lanka.- *Am J Epidemiol.* 2008 Aug 1;168(3):321-8. Epub 2008 Jun 10. ([DOI Direct Link](#))
- [LH as a diagnostic criterion for polycystic ovary syndrome in patients with WHO II oligo/amenorrhoea.](#)
Elevated LH is common in polycystic ovary syndrome (PCOS), but is not part... 22nd August, 2008
Division of Reproductive Medicine, Department of Obstetrics and- *Reprod Biomed Online.* 2008 Jun;16(6):765-71.
- [Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels.](#)
OBJECTIVE: To evaluate the metabolic profiles of adolescents with... 19th August, 2008
Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy.- *Fertil Steril.* 2008 Aug 13. ([DOI Direct Link](#))
- [Sustained clinical inactivity and stabilization of GH/IGF-1 levels in an acromegalic patient after discontinuation of somatostatin analogue treatment.](#)
BACKGROUND: A 38-year-old woman first presented complaining of foot... 19th August, 2008
Department of Endocrinology, Hippokratia General Hospital, Thessaloniki,- *Endocr J.* 2008 May;55(2):351-7. Epub 2008 Apr 1.
- [Postoperative adhesiolysis therapy for intrauterine adhesions \(Asherman's syndrome\).](#)
OBJECTIVE: To evaluate postoperative blunt adhesiolysis after sharp... 15th August, 2008
Minimally Invasive Gynecologic Surgery Center, Newton-Wellesley Hospital,- *Fertil Steril.* 2008 Aug;90(2):409-14. Epub 2008 Jun 20. ([DOI Direct Link](#))
- [Partial 17alpha-hydroxylase/17,20-lyase deficiency-clinical report of five Chinese 46,XX cases.](#)
OBJECTIVESL: To summarize the clinical characteristics of partial... 23rd July, 2008
Department of Obstetrics and Gynecology, Peking Union Medical College- *Gynecol Endocrinol.* 2008

Jul;24(7):362-7. ([DOI Direct Link](#))

- [Primary amenorrhea as a manifestation of polycystic ovarian syndrome in adolescents: a unique subgroup?](#)
*OBJECTIVE: To compare clinical and metabolic features of adolescents...*4th July, 2008
Division of Pediatrics, Assaf Harofeh Medical Center, Tel Aviv University,- Arch Pediatr Adolesc Med. 2008 Jun;162(6):521-5. ([DOI Direct Link](#))
- [Oocyte cryopreservation in a woman with mosaic Turner syndrome: a case report.](#)
*BACKGROUND: Turner syndrome (TS) is the most common sex chromosome...*28th June, 2008
Division of Reproductive Endocrinology and Infertility, Department of- J Reprod Med. 2008 Mar;53(3):223-6.
- [Ovarian function and disease activity in patients with systemic lupus erythematosus.](#)
*OBJECTIVE: Menstrual cycle disturbances frequently occur during the onset...*27th June, 2008
Department of Microcirculation and Inflammation, Institute of- Clin Exp Rheumatol. 2008 May-Jun;26(3):436-41.
- [The use of metformin as first line treatment in polycystic ovary syndrome.](#)
*This study evaluated the use of metformin as first line treatment for...*21st June, 2008
Obstetrics and Gynaecology Department, Portiuncula Hospital, Ballinasloe,- Ir Med J. 2008 Feb;101(2):51-3.
- [Acarbose for polycystic ovary syndrome.](#)
*OBJECTIVE: To review the evidence for use of acarbose in the management of...*18th June, 2008
College of Pharmacy, University of Southern Nevada, Henderson, NV 89104,- Ann Pharmacother. 2008 Jun;42(6):847-51. Epub 2008 May 6. ([DOI Direct Link](#))
- [A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.](#)
*Hyperprolactinemia is a common adverse effect that occurs as a result of...*16th May, 2008
Laboratory of Clinical Psychopharmacology, Beijing Anding Hospital,- J Clin Psychopharmacol. 2008 Jun;28(3):264-370. ([DOI Direct Link](#))
- [Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome.](#)
*BACKGROUND: The aim of this study was to evaluate associations of clinical...*16th May, 2008
Department of Obstetrics and Gynecology, Erlangen University Hospital,- Eur J Endocrinol. 2008 May;158(5):711-9. ([DOI Direct Link](#))
- [Quality of life and marital sexual satisfaction in women with polycystic ovary syndrome.](#)
*Polycystic ovary syndrome affects 5-10% of women in the developed world,...*15th April, 2008
Woman's Health Chair, the Medical University of Silesia, Katowice, Poland.- Folia Histochem Cytobiol. 2007;45 Suppl 1:S93-7.

BioNews Results for Oligomenorrhea

- [Need to know - infertility](#)
Pulse: Aug 22 2008 7:00PM Matching: oligomenorrhea

Oligomenorrhea Clinical Trials:



- [Reproductive Effects of Pesticide, PCB and Mercury Exposure in Laotian Immigrants](#)
Amenorrhea; Dysmenorrhea; Oligomenorrhea; Anovulation; Infertility



Oligomenorrhea Patents:

- 7381409- [Antibodies specific for sclerostin and methods of screening and use therefor](#)
- 5102868- [Method for inhibiting follicular maturation](#)
- 5173404- [Immunoassay for follicular regulatory protein](#)
- 5612312- [Method for treating insulin resistance with IGF-I](#)
- 5637567- [Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties](#)
- 5686408- [Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties](#)
- 5736400- [Method for modifying, diagnosing and screening for IGF-I sensitive cell barriers](#)
- 5767082- [Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists](#)
- 5906979- [Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility](#)
- 4912201- [Monoclonal antibodies and antisera to intragonadal regulatory protein](#)
- 4801577- [Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists](#)
- 4272530- [.DELTA..sup.1,3,5\(10\) -Estratrienes](#)
- 4291028- [Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system](#)
- 4292315- [Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system](#)
- 4562178- [Use of diethylaminoethyl-dextran \(DEAE-D\) as an antihyperinsulinemic drug](#)
- 4657932- [Method of treating prolactin-related disorders](#)
- 4707475- [Agent for lowering serum prolactin levels](#)
- 4734398- [Follicular regulating protein](#)
- 4764502- [Intragonadal regulatory protein](#)
- 6034075- [Method of treating polycystic ovarian syndrome](#)
- 6180803- [19-nor-pregnene derivatives and pharmaceuticals containing such derivatives](#)
- 7105490- [Methods and compositions for treating polycystic ovary syndrome](#)
- 7153678- [Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof](#)
- 7192583- [Methods for modulating bone mineralization](#)
- 7226902- [Ligands for TGF-beta binding proteins and uses thereof](#)
- 7232667- [Keratinocyte growth factor-2 polynucleotides](#)
- 7291593- [Use of fish for treating infertility](#)
- 7303772- [Synergistic phytoceutical compositions](#)
- 7358074- [Human phosphatase RET31, and variants thereof](#)
- 7105489- [Methods and compositions for treating polycystic ovary syndrome](#)
- 6960337- [Methods and compositions for treating benign gynecological disorders](#)
- 6261800- [Luteinizing hormone/choriogonadotropin \(LH/CG\) receptor](#)
- 6265393- [Prevention of endometriosis signs or symptoms](#)
- 6395511- [Nucleic acids encoding a novel family of TGF-.beta. binding proteins from humans](#)
- 6489445- [Polypeptides associated with alterations in bone density](#)
- 6495736- [Compositions and methods for increasing bone mineralization](#)

- 6635672- [Agent for lowering prolactin](#)
- 6693077- [Keratinocyte growth factor-2](#)
- 6803453- [Antibodies associated with alterations in bone density](#)
- 4242335- [Novel 17.alpha.-aryl-steroids](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

